"Androgens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.
Descriptor ID |
D000728
|
MeSH Number(s) |
D27.505.696.399.472.161
|
Concept/Terms |
Androgens- Androgens
- Androgenic Compounds
- Compounds, Androgenic
- Androgen Receptor Agonists
- Agonists, Androgen Receptor
- Receptor Agonists, Androgen
- Androgenic Agents
- Agents, Androgenic
Androgen Effect- Androgen Effect
- Effect, Androgen
- Androgen Effects
- Effects, Androgen
|
Below are MeSH descriptors whose meaning is more general than "Androgens".
Below are MeSH descriptors whose meaning is more specific than "Androgens".
This graph shows the total number of publications written about "Androgens" by people in this website by year, and whether "Androgens" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 3 | 1 | 4 |
1996 | 0 | 1 | 1 |
1997 | 0 | 4 | 4 |
1998 | 2 | 1 | 3 |
1999 | 0 | 1 | 1 |
2000 | 1 | 0 | 1 |
2001 | 1 | 2 | 3 |
2002 | 1 | 0 | 1 |
2003 | 1 | 2 | 3 |
2004 | 2 | 1 | 3 |
2005 | 4 | 3 | 7 |
2006 | 2 | 1 | 3 |
2007 | 1 | 2 | 3 |
2008 | 1 | 2 | 3 |
2009 | 2 | 4 | 6 |
2010 | 3 | 4 | 7 |
2011 | 1 | 2 | 3 |
2012 | 1 | 2 | 3 |
2013 | 2 | 1 | 3 |
2014 | 2 | 1 | 3 |
2016 | 2 | 4 | 6 |
2018 | 2 | 2 | 4 |
2020 | 0 | 1 | 1 |
2021 | 1 | 2 | 3 |
2022 | 0 | 3 | 3 |
2023 | 1 | 7 | 8 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Androgens" by people in Profiles.
-
Facial and genital color ornamentation, testosterone, and reproductive output in high-ranking male rhesus macaques. Sci Rep. 2024 01 31; 14(1):2621.
-
Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles to Treat PCOS. Int J Mol Sci. 2023 Jul 06; 24(13).
-
Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system. Cancer. 2023 10 15; 129(20):3326-3333.
-
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. Eur Urol. 2023 08; 84(2):229-241.
-
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial. Eur Urol. 2023 08; 84(2):156-163.
-
Emerging treatment options for prostate cancer. Expert Rev Anticancer Ther. 2023 06; 23(6):625-631.
-
Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial. J Clin Oncol. 2023 06 10; 41(17):3217-3224.
-
Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial. J Clin Oncol. 2023 06 10; 41(17):3203-3216.
-
Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries. Eur Urol. 2023 05; 83(5):393-401.
-
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022 05 14; 399(10338):1886-1901.